Abstract
Much has been learned about the design and execution of long-term intervention studies from the experience with the recent major trials1–11 evaluating various platelet suppressing drugs in the secondary prevention of myocardial ischemia or cerebral ischemia. These studies have also served to highlight a number of misconceptions and oversights about statistical analysis and interpretation, particularly as they relate to the multiplicity of questions which, of necessity, must be asked of the data both as they accumulate and at the completion of the study.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P.C. Elwood, A.L. Cochrane, M.L. Burr, P.M. Sweetnam, G. Williams, E. Welsby, S.J. Hughes and R. Renton, A randomized controlled clinical trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction, Br. Med. J. 1: 436 (1974).
The Coronary Drug Project Research Group, Aspirin in coronary heart disease, J. Chronic. Pis. 29: 625 (1976).
K. Breddin, Multicenter two-year prospective study on the prevention of secondary myocardial infarction by ASA in comparison with phenprocoumon and placebo, in: “Essais Controles Multicentres Principes et Problems,” J.P. Boissel and C.R. Klimt, eds., I.N.S.E.R.M., Paris (1979).
P.C. Elwood and P.M. Sweetnam, Aspirin and secondary mortality after myocardial infarction, Lancet ii: 1313 (1979).
Aspirin Myocardial Infarction Study Research Group, A randomized controlled trial of aspirin in persons recovered from myocardial infarction, JAMA 243: 661 (1980).
The Persantine - Aspirin Reinfarction Study Research Group, Persantine and aspirin in coronary heart disease, Circulation 62: 449 (1980).
The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: The Anturane Reinfarction Trial, N. Engl. J. Med. 298: 289 (1978).
The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of sudden death after myocardial infarc-tion, N. Engl. J. Med, 302: 250 (1980).
W.S. Fields, N.A. Lemak, R.F. Frankowski and R.J. Hardy, Controlled trial of aspirin in cerebral ischemia, Stroke 8: 301 (1977).
W.S. Fields, N.A. Lemak, R.F. Frankowski and R.J. Hardy, Controlled trial of aspirin in cerebral ischemia. Part II: Surgical group, Stroke 9: 309 ( 1978.
Canadian Cooperative Study Group, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N. Engl. J. Med. 299: 53 (1978).
J.W. Tukey, Some thoughts on clinical trials, especially problems of multiplicity, Science 198: 679 (1977).
D.G. Kleinbaum and L.L. Kupper, “Applied regression analysis and other multivariable methods,” Wadsworth Publishing Company, Belmont, California (1978).
M. Gent, Recent intervention studies of platelet suppressant drugs in cerebral ischemia: Methodological aspects, in: “Drug Treatment and Prevention in Cerebrovascular Disorders,” G. Tognoni and S. Garattini, eds., Elsevier/North Holland Biomedical Press, Amsterdam (1979).
M. Gent and D.L. Sackett, The qualification and disqualification of patients and events in long-term cardiovascular clinical trials, Thromb. Hemostas. 41: 123 (1979).
D.L. Sackett and M. Gent, Controversy in counting and attributing events in clinical trials, N. Engl. J. Med. 301: 1410 (1979).
M. Gent and J. Hirsh, Definition of high risk/high response population for stroke in patients with transient ischemic attacks, Thromb. Hemostas. 41: 40 (1979).
W.H. Harris, E.W. Salzman, C.A. Athanasoulis, A.C. Waltman and R.W. DeSanctis, Aspirin prophylaxis of venous thrombo-embolism after total hip replacement, N. Engl. J. Med. 297: 1246 (1977).
A. Linos, J.W. Worthing, W. O’Fallon, V. Fuster, J.P. Whisnant and L.T. Kurland, Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study, Mayo Clin. Proc. 53: 581 (1978).
J. Hirsh, M. Blajchman and A. Kaegi, The bleeding time, in: “Platelet Function Testing,” DHEW Publication No. (NIH) 78-1087, Washington (1978).
A. Kaegi, G.F. Pineo, A.G. Shimizu, H. Trivedi, J. Hirsh and M. Gent, The prevention of arteriovenous shunt thrombosis by sulfinpyrazone, N. Engl. J. Med. 290: 304 (1974).
M. Johnson, E. Ramey and P.W. Ramwell, Sex and age difference in human platelet aggregation, Nature 253: 355 (1975).
J.G. Kelton, J. Hirsh, C.J. Carter and M.J. Buchanan, Sex differences in the antithrombotic effects of aspirin, Blood 52: 1073 (1978).
G.J. Kelliher, R.K. Dix, M. Jurkiewicz and T.L. Lawrence, Effect of sulfinpyrazone on arrhythmia and death following coronary occlusion in cats, in: “Cardiovascular Actions of Sulfinpyrazone,” M. McGregor, J.F. Mustard, M. Oliver and S. Sherry, eds., Symposia Specialists Inc., Summit, New Jersey (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gent, M. (1981). Some Problems of Multiplicity in Long-Term Intervention Studies. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4055-3_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4057-7
Online ISBN: 978-1-4684-4055-3
eBook Packages: Springer Book Archive